Drug, bio-affecting and body treating compositions inventions

20100022438 - Method of separating carbon nanotubes: A method of separating carbon nanotubes having substantially the same diameter including the steps of: providing a sample of carbon nanotubes; separating individual nanotubes within the sample, and mixing with a solution comprising fibrous protein fibrils so that at least some individual nanotubes form a complex with the protein fibrils,... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100022439 - Nanostructures with high load of active agents: The present invention provides an improved method of loading silica nanostructures with an active agent, comprising exposing a mixture comprising a liquid medium containing an active agent and silica nanostructures to reduced air pressure for a time period, and then returning the mixture to atmospheric air pressure at the end... Agent: Patent Docket Administrator Lowenstein Sandler PC

20100022440 - Vh4 codon signature for multiple sclerosis: The present invention provides for the diagnosis and prediction of multiple sclerosis (MS) in subject utilizing a unique a codon signature in VH4 expressing B cells that has now been associated with MS and not with any other autoimmune disease.... Agent: Fulbright & Jaworski L.L.P.

20100022441 - N-terminal polysialylation: The present invention relates to a composition comprising a population of polysaccharide derivatives of a protein, wherein the protein is insulin or an insulin-like protein and the polysaccharide is anionic and comprises between 2 and 125 saccharide units, and wherein the population consists of substantially only N-terminal derivatives of the... Agent: Morrison & Foerster LLP

20100022442 - Compositions and methods for increasing serum antioxidant concentrations, decreasing serum triglyceride levels, inhibiting insulin-receptor signaling activity, increasing serum ghrelin levels, and decreasing serum tnf-alpha levels: Compositions and methods are provided for increasing serum antioxidant levels, decreasing serum levels of oxidative chemical species, inhibiting insulin-receptor signaling activity, decreasing triglycerides levels, increasing serum ghrelin levels, and decreasing serum TNF-alpha levels. Compositions provided comprise a mixture of zinc-charged, fragmented proteins derived, for example, from serum or milk. Compositions... Agent: Knobbe Martens Olson & Bear LLP

20100022444 - Combination therapy for modulation of activity and development of cells and tissues: The invention as disclosed herein provides methods and compositions for modulation of development and activities of cells and tissues in a subject in need of treatment thereof. The inventive methods and compositions involve the use of a combination therapy that comprises at least two active compositions, the first active composition... Agent: Law Offices Of Khalilian Sira, LLC

20100022443 - Derivatisation of erythropoietin (epo): The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the... Agent: Morrison & Foerster LLP

20100022445 - Biologically active peptides: e

20100022447 - Composition for treating cancer and use thereof: The present invention provides a cyclic peptide containing RRXR motif. The present invention also provides a composition comprising the said cyclic peptide and a pharmaceutical acceptable carrier. The present invention further provides a method for treating cancer.... Agent: Wpat, PC Intellectual Property Attorneys

20100022446 - Use of peptides in combination with surgical intervention for the treatment of obesity: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100022450 - Octreotide implant having a release agent: Methods, formulations and kits are described that allow for the controlled release of octreotide, e.g., octreotide acetate, in a subject.... Agent: Foley And Lardner LLP Suite 500

20100022448 - Peptides: An internally-constrained cyclic oligopeptide comprising a ring of at least six amino acids for specifically binding to a target ligand, wherein the ring comprises a plurality of amino acid domains, each domain comprising at least two epitope-forming amino acids, and two or more associating functional groups positioned so that they... Agent: Cermak Kenealy Vaidya & Nakajima LLP

20100022449 - Receptor-avid exogenous optical contrast and therapeutic agents: Cyanine and indocyanine dye compounds and bioconjugates are disclosed. The present invention includes several cyanine and indocyanine dyes, including bioconjugates of the same, with a variety of bis- and tetrakis (carboxylic acid) homologues. The compounds of the invention may be conjugated to bioactive peptides, carbohydrates, hormones, drugs, or other bioactive... Agent: Thompson Hine L.L.P. Intellectual Property Group

20100022456 - Dimeric prolactin receptor ligands: The patent application relates to antagonistic dimers of prolactin molecules and their use in treating cancer.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100022452 - Nanobodies for the treatment of aggregation-mediated disorders: The present invention relates to improved Nanobodies™ against von Willebrand Factor (vWF), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host... Agent: Wolf Greenfield & Sacks, P.C.

20100022453 - Nogo receptor 1 and fibroblast growth factor interactions: Compositions and methods useful in promoting neuronal growth, synaptic transmission, or neuronal regeneration are described, including, for example, a polypeptide comprising a fragment of NgR1, wherein the NgR1 fragment has reduced FGF2 binding as compared to wild-type NgR1. Also described are chimeric polypeptides comprising the NgR1 fragment and compositions comprising... Agent: Fish & Richardson P.C.

20100022454 - Peptides with high affinity for the prolactin receptor: The present invention is concerned with peptides binding to the prolactin receptor, wherein said peptides have an improved binding via binding site 1 (BS1) to the prolactin receptor. In one embodiment, said improved binding is achieved by mutation of positions 61, 71 and 73.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100022455 - Therapeutic agents comprising elastin-like peptides: The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20100022451 - Use of infant formula with reduced protein content: A method of continuously reducing the circulating level of insulin like growth factor 1 (IGF-1) in the first few months of the life of an infant comprises administering to the 5 infant a nutritional composition comprising proteins in an amount such that the composition contains less than 2.25 g of... Agent: K&l Gates LLP

20100022457 - Sustained release glp-1 receptor modulators: The present invention provides novel pharmaceutical compositions comprising a human glucagon-like peptide-1 (GLP-1)-receptor modulator as an active ingredient in a sustained release formulation.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100022458 - Methods for treating acute acoustic trauma: The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition includes compounds which function as free radical traps such as phenyl butyl nitrone (PBN), free radical scavengers, such as edaravone, resveratrol, ebselen and iron chelator and compounds... Agent: Mcafee & Taft Tenth Floor, Two Leadership Square

20100022459 - Peptides directed for diagnosis and treatment of amyloid-associated diseases: Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X—Y or Y—X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100022460 - C-phenyl glycitol compound: p

20100022461 - Novel derivatives of cyclic compound and the use thereof: Disclosed is tonovel cyclic derivatives having potent inhibiting effect on melanin formation and skin hyper-pigmentation activity with no adverse response to skin. They can be used as the therapeutics for treating and preventing the skin disease caused by over-reproduced melanin.... Agent: Sughrue Mion, PLLC

20100022462 - Appetite suppressant and colon cleansing composition: The present invention provides low calorie, high potency, sugar free compositions and methods for making and using the same. In one embodiment, the composition of the present invention can be used to reduce daily food intake and facilitate detoxification and weight loss.... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20100022463 - Feed additive for laying hen and feed containing the same: A feed additive for laying hens comprising lactobionic acid or a lactobionic acid salt and a feed characterized by containing a feed additive for laying hens comprising lactobionic acid or a lactobionic acid salt and a feed. Namely, a feed additive for laying hens, which is excellent in effect of... Agent: Sughrue-265550

20100022464 - Functional food composition that is rich in phenolic compounds and use of said composition: The invention relates to a functional food composition rich in phenolic compounds, obtained from the combination of citric and olive species extracts, comprising: between 5 and 25% of oleuropein; between 0.1 and 1% of verbascoside, between 0.1 and 1% of hydroxytyrosol, between 1 and 5% of neohesperidin; between 1 and... Agent: Merchant & Gould PC

20100022465 - Method of treating blepharitis: The present invention relates to a method for treating non-infectious, inflammatory chronic posterior blepharitis in a subject. The present invention also relates to a method for treating chronic posterior blepharitis in a subject for over two weeks. The method comprises identifying a subject in need thereof, and topically administering to... Agent: Howery LLP

20100022466 - Thermally-targeted delivery of medicaments including doxorubicin: Elastin-like polypeptide (ELP) serves as a vector for thermally-targeted delivery of therapeutics, including cytotoxic chemotherapeutic drugs such as doxorubicin. Examples of an ELP-based delivery vehicle can comprise: (1) a cell penetrating peptide, such as a Tat protein, (2) ELP, and (3) the lysosomally degradable glycylphenylalanylleucylglycine (GFLG) spacer and a cysteine... Agent: Stites & Harbison PLLC

20100022619 - Compositions and their uses directed to ptpr alpha: Disclosed herein are compounds, compositions and methods for modulating the expression of PTPR.alpha. in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are... Agent: Mcdermott Will & Emery

20100022621 - Construction and use of transfection enhancer elements: Nucleic acids comprising a nucleic acid moiety and two or more transfection enhancer elements (TEE's) according to the general formula (I): Hydrophobic moiety—pH-responsive hydrophilic moiety, wherein said pH sensitive hydrophilic moiety of said TEE is independently a weak acid having a pka of between 4 and 6.5 or is a... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20100022622 - Dbait and its standalone uses thereof: The invention relates to compositions and methods for interfering with the DNA repair of double strand breaks (DSBs). The invention discloses double-stranded nucleic acid molecules that act as baits and hijack the holocomplex of enzymes responsible of DNA DSB sensing, signaling and/or repair pathways, in particular the non-homologous end joining... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100022620 - Epitope reduction therapy: The present invention provides the use of an inhibitor of glycolipid biosynthesis in the manufacture of a medicament for the treatment of a glycolipid-mediated autoimmune disease.... Agent: Nixon & Vanderhye, PC

20100022618 - Long interfering nucleic acid duplexes targeting multiple rna targets: Long interfering nucleic acid (iNA) duplexes, which are at least 30 nucleotides in length, which have at least one nick or nucleotide gap in the antisense or the sense strands or in both the sense and antisense strands. These long iNA duplexes do not induce an interferon response when transfected... Agent: Paul G. Lunn

20100022623 - Methods and compositions for the treatment of eye disorders with increased intraocular pressure: The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of... Agent: King & Spalding

20100022624 - Methods of treating smooth muscle cell disorders: The present invention provides methods of detecting cells showing smooth muscle differentiation. The present invention further provides methods of detecting tumor cells. The present invention further provides compositions and methods for treating smooth muscle cell disorders.... Agent: Bozicevic, Field & Francis LLP

20100022625 - Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use: Provided herein is a crystallized ternary structure of aldose reductase (AR) bound to NADPH and γ-glutamyl-S-(1,2-dicarboxyethyl)cysteinylglycine (DCEG). Also provided are specific inhibitors of glutathione-aldehyde binding to aldose reductase which are designed via at least computer modeling of the ternary AR:NADPH:DCEG structure and methods of designing and of screening the inhibitors... Agent: Benjamin Aaron Adler Adler & Associates

20100022628 - Alternative oxidase and uses thereof: The invention relates to a method for combating disorders affecting the mitochondrial oxidative phosphorylation system by allotopic expression of the cyanide-insensitive alternative oxidase (AOX) in human cells. The successful expression of AOX in human cells and in Drosophila has been shown to confer spectacular cyanide-resistance to mitochondrial substrate oxidation, alleviate... Agent: Marshall, Gerstein & Borun LLP

20100022626 - Modulators of cell migration and methods of identifying same: The present invention relates to a method of measuring cell migration, the method comprising (a) contacting a cell with a plurality of polystyrene non-fluorescent beads so as to generate a migratory track; and (b) analyzing at least one morphometric parameter of said migratory track, the morphomotric parameter being indicative of... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100022627 - Predictive biomarkers for chronic allograft nephropathy: The invention relates to the analysis and identification of genes that are modulated in transplant rejection. This alteration of gene expression provides a molecular signature to accurately detect transplant rejection.... Agent: Novartis Corporate Intellectual Property

20100022467 - Anti-cancer phosphonate analogs: The invention is related to phosphorus substituted anti-cancer compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Viksnins Harris & Padys Pllp

20100022468 - Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection: The present invention provides nucleoside cyclic phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as pre-cursors to... Agent: Merck And Co., Inc

20100022469 - Anthelminthic formulations: The present invention relates to veterinary or pharmaceutical antiparasitic formulations which may comprise a macrocyclic lactone, one or more alcohol cosolvents and an oil wherein the crystallization of the macrocyclic lactone is minimalized. This invention also provides for, inter alia, antiparasitic formulations for the treating, controlling and preventing of endo-... Agent: Judy Jarecki-black, Ph.d, J.d. Merial Ltd.

20100022472 - Liquid, eye-instillable preparations comprising sodium hyaluronate: A liquid, eye-instillable preparation comprises a viscosity-enhancing agent comprised of one or both of sodium hyaluronate and chondroitin sulphate, a preservative comprised of polyhexanide, and one or more carriers in which the agent and the preservative are dispersed.... Agent: Calfee Halter & Griswold, LLP

20100022470 - Method for treating allergic diseases: The present invention relates to use of polysaccharides obtained from Dendrobium for treating an allergic disease or for reducing airway-remodeling caused by inflammation.... Agent: Ipc Intellectual Property Connections, Inc.

20100022471 - Oral moisturizer for alleviating dry mouth: An oral moisturizer is disclosed to provide relief from dry mouth. The moisturizer may be provided in different flavors that are palatable, with clinical benefits such as anti-nausea, appetite stimulant, etc., in addition to relief from the deteriorating dental effects of dry mouth. One disclosed oral moisturizer includes glycerin, xylitol,... Agent: Miller, Matthias & Hull

20100022473 - Use of lipid conjugates in the treatment of diseases associated with vasculature: wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol, Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan; and... Agent: Pearl Cohen Zedek Latzer, LLP

20100022474 - Polymer controlled induced viscosity fiber system and uses thereof: The present invention relates generally to a method of blunting the postprandial glycemic response in a human by feeding an induced viscosity fiber system. The invention also relates to an induced viscosity fiber system and the liquid products that incorporate the induced viscosity fiber system. Further, the invention relates to... Agent: Ross Products Division Of Abbott Laboratories Department 108140-ds/1

20100022475 - Novel triazolopyrimidine derivatives: The present invention relates to novel triazolopyrimidine derivatives of formula I as active ingredients which have microbiocidal activity, in particular fungicidal activity(I): wherein the substituents are as defined in claim 1. Characterizing feature is the cyclic silyl group.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100022476 - Pyrazolylamino substituted quinazoles for the treatment of cancer: The invention provided a compound of formula: (I) for use in the treatment of disease, in particular proliferative diseases such as cancer and for use in the preparation of medicaments for use in the treatment of proliferative diseases; the invention also processes for the preparation of such compounds, as well... Agent: Astrazeneca R&d Boston

20100022477 - Fused aromatic ptp-1b inhibitors: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.... Agent: Merck And Co., Inc

20100022478 - Chiral compounds substituted with phosphonate acid ester functions or phosphonic acid functions: The present invention relates to novel compounds that contain PNA units substituted with phosphonic acid ester functions or phosphonic acid functions, and have at least one chiral center. The compounds may be used for the treatment of viral diseases, such as AIDS.... Agent: Frommer Lawrence & Haug

20100022479 - Cellular gradient polymer composites: The invention relates to a foamed polymer composite product incorporating several fillers and/or fibres and several pores characterized by the fact that it shows two distinct gradients, namely a filler and/or fibre density gradient and a pore density gradient. The polymer composite according to the invention may advantageously be used... Agent: Nixon & Vanderhye, PC

20100022480 - Solid oral dosage form containing an enhancer: The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain... Agent: Myers Bigel Sibley & Sajovec

20100022481 - Drug carriers, their synthesis, and methods of use thereof: Drug carriers, methods of synthesizing, and methods of use thereof are provided.... Agent: Dann, Dorfman, Herrell & Skillman

20100022482 - Asmase inhibitors: u

20100022483 - Substituted tetracycline compounds: The present invention pertains, at least in part, to methods of treating a microorganism-associated infection in a subject comprising administering to said subject an effective amount of a tetracycline compound.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100022484 - 4-chromenonyl-1,4-dihydropyridines and their use: The present application relates to novel 4-chromenonyl-1,4-dihydropyridines, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100022486 - Compounds: e

20100022485 - Formulations comprising a vitamin and the use thereof to make fortified feed and personal care formulations: The invention relates to aqueous formulations comprising alkoxylated castor oils with 15-25 ethyleneoxy units and a vitamin, preferably a fat-soluble vitamin, as well as to the use of such formulations in the process to administer the vitamin to an animal, or to make personal care formulations comprising the vitamin.... Agent: Akzo Nobel Inc.

20100022487 - Method, device, and kit for maintaining physiological levels of steroid hormone in a subject: A method, device, or kit is provided which maintain a substantially physiological cyclic pre-menopausal level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or... Agent: Searete LLC Clarence T. Tegreene

20100022488 - Method, device, and kit for maintaining physiological levels of steroid hormone in a subject: A method, device, or kit is provided which maintain a substantially physiological cyclic pre-menopausal level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or... Agent: Searete LLC Clarence T. Tegreene

20100022489 - Method, device, and kit for maintaining physiological levels of steroid hormone in a subject: A method, device, or kit is provided which maintain a substantially physiological level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid... Agent: Searete LLC Clarence T. Tegreene

20100022491 - 4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7yl compounds for modulation of b2-adrenoreceptor activity: The present invention provides compounds of formula (I) (A chemical formula should be inserted here—please see paper copy enclosed herewith) wherein Ra, Rb, R1, R2, R3, R4, R5, R6 and R29 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100022492 - Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set: The invention provides for a therapeutic causing contraction of a mucosal tissue whereby various diseases relating to mucosal tissues can be easily, safely and treated with minimal invasiveness, a method of treating various diseases relating to mucosal tissues with the use of the therapeutic causing contraction of a mucosal tissue,... Agent: Frommer Lawrence & Haug

20100022490 - Zilpaterol enantiomer compositions and methods of making and using such compositions: This invention is directed generally to zilpaterol enantiomer compositions and, in particular, to compositions comprising the 6R,7R zilpaterol enantiomer. This invention is also directed to processes for making such compositions; methods for using such compositions to, for example, increase the rate of weight gain, improve feed efficiency, and/or increase carcass... Agent: Traskbritt, P.C.

20100022493 - Use of mometasone furoate for treating airway passage and lung disease: The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20100022494 - Method, device, and kit for maintaining physiological levels of steroid hormone in a subject: A method, device, or kit is provided which maintain a substantially physiological level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid... Agent: Searete LLC Clarence T. Tegreene

20100022496 - Galenical form for the administration of active ingredients by transmucous means: A galenical form for the administration transmucously of at least one active ingredient, characterized in that the active ingredient is in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 20% by mass of alcohol so as to allow rapid absorption of the active ingredient... Agent: Young & Thompson

20100022497 - Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on apoe allelic profile of a mammalian subject: A method for treating cardiovascular disease in a mammalian subject includes providing to the subject at least one treatment regimen including at least one estrogen receptor modulator, wherein the at least one treatment regimen is determined based on the APOE allelic profile in the subject, and based on the steroid... Agent: Searete LLC Clarence T. Tegreene

20100022495 - Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis: Endoplasmic reticulum stress has been found to be associated with the genetic disease tuberous sclerosis. Tuberous sclerosis is cause by defects in the two genes, TSC1 and TSC2. Agents that modulate ER stress may be used to treat tuberous sclerosis and other hamartomatous diseases. In particular, 4-phenyl butyric acid (PBA)... Agent: Edwards Angell Palmer & Dodge LLP

20100022498 - Steroids as agonists for fxr: d

20100022499 - Heterocyclic compounds, combinatorial libraries thereof and methods of selecting drug leads: Heterocyclic compounds having a relatively flexible backbone are used to create combinatorial libraries that permit screening for lead compounds and selection of drug candidates for a variety of uses in human and veterinary medicine as well as in agriculture. The compounds of the library generally differ in ring size and... Agent: Winston & Strawn LLP Patent Department

20100022500 - Macrocyclic lactams and pharmaceutical use thereof: wherein R1, R2, R3, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use... Agent: Foley And Lardner LLP Suite 500

20100022501 - Injectable or orally deliverable formulations of azetidine derivatives: The invention concerns injectable or orally deliverable binary or ternary formulations of azetidine derivatives. The azetidine derivatives used in the inventive pharmaceutical compositions can be represented by the general formulae (Ia) or (Ib), wherein Ar is an aromatic or heteroaromatic group optionally substituted by one or more among (C1-C4)alkyl, halogen,... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100022504 - Methods for treating latent tuberculosis: A method for treating individuals affected with latent tuberculosis comprising a step of administering an effective amount of one or more carbapenem compounds to the said individuals.... Agent: Young & Thompson

20100022506 - Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors: or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, M and R11 are as defined herein. The compounds of Formula (I) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa,... Agent: Louis J. Wille Bristol-myers Squibb Company

20100022505 - Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof: Ra, Rb and Rc are defined as in claim 1, their tautomers, their stereoisomers, their mixtures and their salts, in particular their physiologically acceptable salts with inorganic or organic acids and bases, which have valuable pharmacological properties, in particular an inhibitory action on the signal transduction mediated by tyrosine kinases,... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100022503 - Aminopyrazole kinase inhibitors: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100022502 - Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Inc.

20100022507 - Aminopyrimidines useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Inc.

20100022509 - Inhibitors of mshc and homologs thereof, and methods of identifying same: The present invention utilizes three families of bacterial enzymes, which play a key role in mycothiol biosynthesis. The three families are bacterial cysteine:glucosaminyl inositol ligases (MshC) with catalytic ligase activity for ligation of glucosaminyl inositol and cysteine, bacterial acetyl-CoA:Cys-GlcN-Ins acetyltransferases (MshD) with catalytic activity for addition of an acetyl group... Agent: Dla Piper LLP (us)

20100022508 - Antiviral compounds: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Gilead Sciences Inc

20100022510 - Crystalline forms: The present invention is directed to a crystalline form the pharmaceutical compound 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine as well as compositions, preparations, and pharmaceutical uses thereof.... Agent: Pepper Hamilton LLP

20100022511 - Stabilized atypical antipsychotic formulation: A pharmaceutical composition that contains an atypical antipsychotic drug and succinic acid, fumaric acid or a mixture of succinic acid and fumaric acid.... Agent: Hedman & Costigan P.C.

20100022512 - Compositions of chk1 inhibitors and cyclodextrin: Compositions containing at least one Chk1 inhibitor and at lease one cyclodextrin are disclosed. Also disclosed are methods of treating a cancer or potentiating a cancer treatment with a composition comprising at least one Chk1 inhibitor and at least one cyclodextrin.... Agent: Eli Lilly & Company

20100022513 - Organic compounds: m

20100022515 - Compounds and compositions as modulators of gpr119 activity: The invention provides compounds, pharmaceutical compositions comprising compound of following formula (I), and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119 (G protein-coupled receptor 119) such as obesity, diabetes and hyperlipidemia.... Agent: Genomics Institute Of The Novartis Research Foundation

20100022514 - Heterocycle compounds and methods of use thereof: The invention relates to the use of compounds in the treatment of deacetylase-associated diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100022516 - 4,5-disubstituted-2-aryl pyrimidines: wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I and II bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to... Agent: Edwards Angell Palmer & Dodge LLP

20100022517 - Ophthalmic formulation of rho kinase inhibitor compound: The present invention relates to an aqueous pharmaceutical formulation comprising at least one inhibitor of Rho-associated protein kinase (ROCK). The aqueous pharmaceutical formulation comprises 0.01-0.4% w/v of ROCK inhibitor(s), a non-ionic surfactant in an amount of 0.01-2% w/v, and a tonicity agent to maintain a tonicity between 220-360 mOsm/kG, at... Agent: Howery LLP

20100022518 - Novel heterocyclyl compounds: e

20100022519 - Heterocyclic-substituted piperidine compounds and the uses thereof: The invention relates to Heterocyclic-Substituted Piperidine Compounds, compositions comprising an effective amount of a Heterocyclic-Substituted Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Heterocyclic-Substituted Piperidine Compound.... Agent: Dechert LLP

20100022520 - Malonyl-coa acetyltransferase inhibitors against antibiotic resistant bactertia: Compounds characterized by thiolactone or thiomorpholino cores display useful antibiotic and radioprotective properties. The latter properties are believed to arise from an ability of the compounds to inhibit proteins involved in apoptosis.... Agent: Foley And Lardner LLP Suite 500

20100022521 - Compounds: The present invention relates to new mGluR1 and mGluR5 receptor subtype preferring ligands of formula (I) wherein X represents a group selected from SO, SO2; Y represents a group selected from (CH2)n, NH, NHCH2; n is an integer of 0 to 1; Z is H or monosubstituted by alkyl, nitro,... Agent: Fish & Richardson P.C.

20100022522 - Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.... Agent: Fish & Richardson PC

20100022523 - 3-aminobenzamide compounds and vanilloid receptor subtype 1 (vr1) inhibitors: The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R1 is a C1-6 alkyl group which may be substituted, R2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group... Agent: Leydig Voit & Mayer, Ltd

20100022524 - Tricyclic tetrahydroquinoline antibacterial agents: The invention includes tetrahydroquinoline and related compounds of formula I, and pharmaceutical compositions thereof, that exhibit useful antibacterial activity against a wide range of human and veterinary pathogens.... Agent: Pfizer Inc Mary J Hosley

20100022525 - Arginine derivatives with np-i antagonistic activity: The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100022526 - Pyridazine derivatives, processes for their preparation and their use as fungicides: The present invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in claim 1, which are useful as fungicides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100022527 - Biphenyl substituted spirotetronic acids and their use for the treatment of retroviral diseases: The present invention relates to novel substituted spirotetronic acids (I) in which R1 and R2, together with the carbon atom to which they are bonded, form a group of the formula (1), (2), (3) or (4), whereby * represents the carbon atom to which R1 and R2 are bonded, to... Agent: Morrison & Foerster LLP

20100022528 - Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use: Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits... Agent: Darby & Darby P.C.

20100022529 - Amidophenoxyindazoles useful as inhibitors of c-met: The present invention provides amidophenoxyindazole compounds useful in the treatment of cancer.... Agent: Eli Lilly & Company

20100022530 - Tetrahydrobenzoisoxazole and tetrahydroindazole derivatives as modulators of the mitotic motor protein: Compounds of the formula (I) in which A1, A2, R1, X1, X2, X3, Y, R2, Cy and n have meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20100022533 - Compositions and methods for inducing cell dedifferentiation: The present invention provides compounds, compositions and methods for dedifferentiating lineage committed mammalian cells into stem cells. The present invention also provides methods of inducing dedifferentiation of lineage committed mammalian cells into stem cells, which can be further differentiated into various lineage committed cells. Methods of identifying additional compounds useful... Agent: Townsend And Townsend And Crew, LLP

20100022531 - Novel compounds as p2x7 modulators and uses thereof: Compounds are disclosed that have a formula represented by the following (1), the compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.... Agent: Klauber & Jackson

20100022532 - Use of a kinase inhibitor for the treatment of particular resistant tumors: The invention provides low molecular weight compounds, namely 1H-thieno[2,3-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find... Agent: Scully Scott Murphy & Presser, PC

20100022534 - 2-benzimidazolyl-6-morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders: The invention concerns pyrimidine derivatives of Formula (I) wherein each of p, R1, R2, q, R3, r, R4, s, t, X1 and Q1 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in a method for producing an anti-proliferative... Agent: Astrazeneca R&d Boston

20100022535 - 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors: 2-pyridyl-substituted imidazoles which are used advantageously in the treatment of diseases mediated by ALK 5 or ALK 4 inhibitors or both.... Agent: The Nath Law Group

20100022536 - Inhibitors of cytosolic phospholipase a2: p

20100022538 - 5-fluoro pyrimidine derivatives: This present disclosure is related to the field of 5-fluoro pyrimidines and their derivatives and to the use of these compounds as fungicides.... Agent: Dow Agrosciences LLC

20100022537 - I-pheny 1-3,4-dihydropyrimidin-2(1h)-one derivatives and their use: This invention relates to novel heterocyclic derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.... Agent: Edwards Angell Palmer & Dodge LLP

20100022539 - Isoxazole compounds as histamine h3 modulators: Certain isoxazole compounds are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20100022540 - Triazole derivatives ii: Novel triazole derivatives of the formula (I) in which R1—R6 and Y have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.... Agent: Millen, White, Zelano & Branigan, P.C.

20100022541 - Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors: The invention relates to new compounds having heptose synthesis inhibitory properties, of formula (I) or a pharmaceutically acceptable salt, or prodrug thereof, wherein A is an aryl or heterocycle, optionally substituted by one or several identical or different R such as H, C1-C10 alkyl, C1-C10 alkyl-OR1, C1-C10 alkyl-NR1R1, alkoxy, hydroxy,... Agent: Nixon & Vanderhye, PC

20100022542 - Compounds exhibiting thrombopoietin receptor agonism: e

20100022544 - Cyclically substituted 3,5-dicyano-2-thiopyridines and use thereof: The present application relates to novel 4-cycloalkyl- and 4-heterocycloalkyl-3,5-dicyano-2-thio-pyridine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of hypertension and other cardiovascular... Agent: Edwards Angell Palmer & Dodge LLP

20100022543 - Cycloalkylidene and heterocycloalkylidene inhibitor compounds: The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.... Agent: Harness, Dickey, & Pierce, P.l.c

20100022545 - Metabotropic glutamate receptor isoxazole ligands and their use as potentiators - 286: e

20100022546 - Adamantyl diamide derivatives and uses of same:

20100022547 - Compounds and methods for treating mammalian gastrointestinal parasitic infections: One aspect of the present invention relates to compounds, and pharmaceutically acceptable salts and prodrugs thereof, that are useful as inhibitors of IMPDH. The invention also provides pharmaceutical compositions comprising the compounds of the invention which selectively inhibit parasitic IMPDH. In certain embodiments, the present invention relates to selective inhibition... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100022548 - Use of n-heterocyclylmethylbenzamides in therapeutics: e

20100022549 - Alpha-helix mimetic with functionalized pyridazine: The synthesis of new α-helix scaffolds mimicking i, i+3 or i+4, i+7 residues, was accomplished. The common pyridazine heterocycle originates from the easily available dimethyl pyridazine-3,6-dicarboxylate building block. These scaffolds may be thought of as synthetic counterparts of amphiphilic α-helices having a hydrophilic face along one side and a hydrophobic... Agent: Townsend And Townsend And Crew, LLP

20100022550 - Tetrahydrocarbazole derivatives useful as androgen receptor modulators: The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male... Agent: Eli Lilly & Company

20100022551 - Trimetazidine for use in the treatment of fibromyalgia syndrome and related conditions: The present invention provides a method for treating certain rheumatic conditions such as fibromyalgia syndrome, chronic fatigue syndrome, myofascial pain syndrome, and Gulf War syndrome, among others, by administration of trimetazidine, along with related compositions and kits.... Agent: Frommer Lawrence & Haug

20100022552 - Kmup-1 capable of treating hypertension: A method for treating a spontaneous hypertension or a cardiomyocyte hypertrophy is provided. The method comprises a step of administering to a mammal a therapeutically effective amount of a compound of 7-[2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1,3-dimethyl xanthine.... Agent: Volpe And Koenig, P.C.

20100022553 - Therapeutic combination comprising an aurora kinase inhibitor and imatinib: The present invention provides a therapeutic combination comprising (a) a compound 1 of formula (A) as set forth in the specification and (b) a BCR-ABL kinase inhibitor selected from the group consisting of Imatinib, Dasatinib, Nilotinib, Bosutinib and Inno-406, wherein the active ingredients are present in each case in free... Agent: Scully Scott Murphy & Presser, PC

20100022554 - Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia: e

20100022555 - Novel derivatives: The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100022556 - Therapeutic combinations comprising a long acting dihydropyridine calcium-channel blocker and a statin: A medicament comprising (±)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester (manidipine) or a physiologically acceptable salt and a statin or a physiologically acceptable salt.... Agent: Ladas & Parry LLP

20100022557 - Radioprotector compounds and related methods: The invention relates to radioprotectors of formula (I), processes for their preparation and their use in protecting biological materials from radiation damage. In diagnostic and therapeutic radiology, particularly in cancer radiotherapy, the radioprotectors of the present invention may be used to protect certain normal tissues or structures from radiation damage.... Agent: Sughrue Mion, PLLC

20100022558 - Treatment of insomnia: The invention relates to the use of Flibanserin for the preparation of medicaments useful for the treatment of Insomnia.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100022559 - Bisoximes as fungicides: The invention relates to the novel use of bisoximes, some of which are known, for controlling unwanted microorganisms, and to processes for their preparation, and also to novel bisoximes, to processes for their preparation and to their use for controlling unwanted microorganisms and insects in crop protection and in the... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100022560 - Thiophene pyrazolopyrimidine compounds: The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and the use of such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.... Agent: Eli Lilly & Company

20100022561 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Wilson, Sonsini, Goodrich & Rosati

20100022563 - Phosphodiesterase inhibitor treatment: Methods and compositions are disclosed for the treatment of diseases or conditions produced by or associated with low cyclic nucleotide levels. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal and pulmonary administration.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100022562 - Use of plant growth regulators to reduce abscisic acid related plant leaf yellowing: The present invention describes methods for maintaining ABA-induced drought tolerance while reducing ABA-induced leaf yellowing through the combination of ABA with selected plant growth regulators. The present invention also describes a method of using selected ABA analogs to reduce water use with minimal leaf yellowing.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100022564 - Purine and deazapurine derivatives as pharmaceutical compounds: The invention provides a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR5; J1-J2 is N═C(R6), (R7)C═N, (R8)N—C(O), (R8)2C—C(O), N═N or (R7)C═C(R6); E is a monocyclic carbocyclic or heterocyclic group of 5 or 6 ring members, the heterocyclic group containing up... Agent: Heslin Rothenberg Farley & Mesiti PC

20100022565 - Pharmaceutical compositions: Provided is a pharmaceutical composition comprising a calcilytic agent which, when administered orally to a subject induces a rapid and short-lasting absorption of the calcilytic agent and/or a rapid and short-lasting release of the parathyroid hormone.... Agent: Novartis Corporate Intellectual Property

20100022566 - Quinazoline derivatives and pharmaceutical compositions thereof: The present invention relates to novel quinazoline derivatives with less skin irritation and an excellent action of strongly suppressing scratching behavior, and pharmaceutical compositions containing a quinazoline derivative as an active ingredient. The present invention is directed to the quinazoline derivatives represented by the general formula [1] or pharmaceutically acceptable... Agent: Darby & Darby P.C.

20100022567 - Compositions containing pufa and/or uridine and methods of use thereof: This invention provides methods of enhancing brain development; increasing or enhancing intelligence; increasing or enhancing synthesis and levels of phospholipids, synapses, synaptic proteins, and synaptic membranes by a neural cell or brain cell, comprising contacting a subject or a pregnant or nursing mother thereof with a composition comprising an omega-3... Agent: Pearl Cohen Zedek Latzer, LLP

20100022568 - Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis: This present invention relates to the use of an endothelin receptor antagonist for the preparation of a medicament for the treatment of early stage idiopathic pulmonary fibrosis.... Agent: Hoxie & Associates LLC

20100022569 - Inhibitors of tyrosine kinases: The present invention relates to the use of pyrimidylaminobenzamide compounds for the preparation of a drug for the treatment of diseases that respond to modulation of Ephrin receptor kinase, especially EphB4, activity, especially for the curative and/or prophylactic treatment of proliferative diseases, and to a method of treating diseases that... Agent: Dilworth & Barrese, LLP

20100022570 - Novel microbiocides: Compounds of the formula (I) in which the substituents are as defined in claim 1 are suitable for use as microbiocides. Formula (I), wherein X is oxygen or sulfur; A is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100022573 - Inhibitors of akt activity: The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in... Agent: Merck And Co., Inc

20100022572 - Novel spiro compound and medicine comprising the same: e

20100022571 - Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors: The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type IV selective inhibitors are provided. Prepared compounds correspond to structure XIV.... Agent: Ranbaxy Inc.

20100022574 - Methods to treat pain using an alpha-2 adrenergic agonist and an endothelin antagonist: The present invention relates, in general to treatment of pain comprising administering an alpha-2 adrenergic agonist and an endothelin antagonist, wherein administration of the agents acts as an analgesic and ameliorates pain in a subject.... Agent: Marshall, Gerstein & Borun LLP

20100022575 - Oxymatrine compositions and related methods for treating and preventing chronic infectious diseases: Compositions and methods for treating chronic infectious diseases using substantially pure oxymatrine or pharmaceutically acceptable salts or esters thereof are disclosed. In one embodiment described herein, the chronic infectious disease is chronic fatigue syndrome. Further described are compositions having an anti-infective amount of substantially pure oxymatrine or pharmaceutically acceptable salts... Agent: K&l Gates LLP

20100022577 - Dry syrup containing loratadine: Dry syrup preparations comprising loratadine as a hydrophobic medicinal drug are provided. The loratadine dry syrup preparations can be produced using a cellulose material or an argininic acid salt together with sugar.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20100022576 - Stable and bioavailable formulations and a novel form of desloratadine: An active pharmaceutical ingredient comprising 95% of form I of desloratadine and 5% of form II of desloratadine is disclosed. Also disclosed are a process for its preparation as well as a bioavailable and stable formulation containing this active pharmaceutical ingredient for the treatment of allergic diseases like allergic rhinitis,... Agent: Manelii Denison & Selter PLLC

20100022578 - Macrocyclic inhibitors of hepatitis c virus:

20100022579 - Substituted tetrahydroquinolines: Compounds of the formula (I), in which R1, R2, R3, R4, R5, X, Y, W, Q1, Q2, Z, s and m have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20100022580 - New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole compounds and methods of use thereof: This disclosure relates to new tricyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds are described, including new 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole compounds. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment... Agent: Morrison & Foerster LLP

20100022581 - Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity: i

20100022583 - Pyridinyl modulators of gamma-secretase: The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, X, R1 R2, R3, R4, R5, R6, R7, R8, and R9 are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with γ-secretase activity, including Alzheimer's... Agent: Philip S. Johnson Johnson & Johnson

20100022582 - Tetrahydroisoquinoline compound and medicinal use thereof: The present invention provide a tetrahydroisoquinoline compound having a superior ACAT-inhibitory activity and/or anti-oxidation action, particularly, novel compound represented by the formula (I) (wherein each symbol is as described in the specification) and a pharmaceutically acceptable salt thereof.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100022584 - Modulation of glutamine synthetase activity: Methods of screening and designing compounds as inhibitors of glutamine synthetase are provided herein. Compounds, e.g., serine protease inhibitors, and compositions comprising the same, that are useful for the treatment, prevention, and/or amelioration of bacterial infections, including Mycobacterium tuberculosis, are also provided.... Agent: Ladas & Parry LLP

20100022585 - Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds: Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a... Agent: Michael Best & Friedrich LLP

20100022586 - Bicyclic heteroaryl inhibitors of pde4: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PD E4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.... Agent: Global Patent Group - Kal

20100022587 - Derivatives of 2-phenyl-3-hydroxyquinoline-4(1h)-one and methods of their preparation and utilization: Derivatives of 2-phenyl-3-hydroxyquinoline-4(1H)-one of the general formula (II), where X represents a nitro group, amino group, and Y represents an atom of halogen, oxygen or sulphur substituted by C1 to C6 alkyl or phenyl group, whereby both the alkyl and phenyl group may be further substituted and the substituents may... Agent: Ostrolenk Faber Gerb & Soffen

20100022588 - Pharmaceutical carrier composition and pharmaceutical composition: The present invention relates to a pharmaceutical carrier composition and a pharmaceutical composition comprising said pharmaceutical carrier composition. The pharmaceutical composition comprises: (a) at least 20% (w/w) of the composition of a sugar or a sugar alcohol; (b) one or more pharmaceutically acceptable excipients; (c) one or more pharmaceutically active... Agent: The Nath Law Group

20100022589 - Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase: e

20100022594 - Heterocyclic sulfonamide inhibitors of beta amyloid production:

20100022590 - Novel compounds: and pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides thereof, which are modulators of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the preparation of a medicament for the treatment of... Agent: Edwards Angell Palmer & Dodge LLP

20100022591 - Piperidine gpcr agonists: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.... Agent: Osi Pharmaceuticals, Inc.

20100022593 - Process for producing anticancer agent ll-d45042: m

20100022592 - Thiazole derivatives as modulators of g protein-coupled receptors: The invention provides compounds of formula (IA) or (IB) and pharmaceutical compositions thereof, which are useful for modulating G protein-coupled receptor 120 (GPR120), and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated GPR120.... Agent: Genomics Institute Of The Novartis Research Foundation

20100022595 - Benzenesulfonamide compounds and their use as blockers of calcium channels: The invention relates to piperidinyl and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1-R3, Z and q are defined as set forth in the specification. The invention is also directed to the use compounds of Formula (I) to treat, prevent or ameliorate a... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100022596 - Epothilone analogues: The invention relates to analogues of epothilones, uses and methods of making the same.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100022597 - 2-adamantyl-butyramide derivatives as selective 11beta-hsd1 inhibitors: The present invention relates to 2-adamantyl-butyramide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension... Agent: Millen, White, Zelano & Branigan, P.C.

20100022599 - Dual-acting antihypertensive agents: wherein: Ar, r, Z, X, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process... Agent: Theravance, Inc.

20100022598 - Substituted inmidazoles as bombesin receptor subtype-3 modulators: Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.... Agent: Merck And Co., Inc

20100022600 - Methods and compositions for treating central nervous system tumors: A method of treating a central nervous system tumor in a subject includes administering a therapeutically effective amount of at least one PPARγ agonist or a derivative thereof to the tumor in the subject.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20100022601 - Sulfonamide compounds and the use: The sulfoneamide compounds having the following Formula (1), which can be used as an effective component of a CaSR antagonizing agent useful for prophylaxis and/or treatment of bone disorders including osteoporosis and etc., are provided. The compounds have an excellent activity of promoting PTH secretion. In addition, the compounds are... Agent: Greenblum & Bernstein, P.L.C

20100022602 - Pre-mixed, ready-to-use iv bolus nicardipine compositions and methods of use: Provided herein are ready-to-use premixed bolus injection pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.... Agent: Patent Docket Administrator Lowenstein Sandler PC

20100022603 - Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use: wherein the various substituents are defined herein, including their physiologically acceptable salts. Processes for the preparation of compounds are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating and other neurodegenerative... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100022604 - Prophylactic or therapeutic agent for alopecia: Disclosed is a novel therapeutic agent which is useful for the prevention or treatment of alopecia. Specifically disclosed is a prophylactic or therapeutic agent for alopecia, which comprises 1-[2-((2S)-2-{5-[(3,4-dimethoxyphenoxy)methyl]-1,2,4-oxadiazol-3-yl}pyrrolidin-1-yl)-1,1-difluoro-2-oxoethyl]-3,3,5,5-tetramethylcyclohexanol as an active ingredient.... Agent: Sughrue Mion, PLLC

20100022605 - N-hydroxyamide derivatives possessing antibacterial activity: Described herein are N-hydroxyamlde antibacterial compounds, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical compositions compound of Formula (I): or a salt, solvate ti hydrate thereof, wherein A is (a) eachindicates a point of attachment.... Agent: Pfizer Inc Mary J Hosley

20100022606 - Method for reducing odor in personal care products: A personal care composition which contains 25-200 ppm of 2-methyl-4-isothiazolin-3-one and at least one hydroquinone radical scavenger, and a method for reducing odor arising in personal care compositions containing 2-methyl-4-isothiazolin-3-one.... Agent: Rohm And Haas Company Patent Department

20100022607 - Diazonamide analogs: Novel diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided.... Agent: Morrison & Foerster LLP

20100022608 - Non-steroidal anti-inflammatory drugs for cough: The use of a non-steroidal anti-inflammatory drug for the treatment of nonproductive cough caused by viruses or bacteria and a combination of at least one non-steroidal anti-inflammatory drug with at least one antitussive in a formulation to treat coughs.... Agent: Bayer Healthcare LLC Consumer Care Division

20100022609 - Novel crystalline forms of temozolomide: Disclosed are novel crystalline forms of Temozolomide, methods of preparation thereof, medicaments including the novel crystalline forms of Temozolomide, and uses thereof in the treatment of medical conditions.... Agent: Leydig Voit & Mayer, Ltd

20100022610 - New crystalline forms: A salt of the compound N-{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}ethanesulfonamide, which is an ethanesulphonic acid salt, a sulphuric acid salt, an ethane disulphonic acid salt, a hydrochloric acid salt, a hydrobromic acid salt, a phosphoric acid salt, an acetic acid salt, a fumaric acid salt, a maleic acid salt, a tartaric acid salt, a... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100022611 - 1,5-diaryl-pyrazoles as cannabinoid receptor neutral antagonists useful as therapeutic agents: The present invention pertains to cannabinoid (CB) receptor neutral antagonists, and especially CB1 neutral antagonists, and including, for example, certain 1,5-di-aryl-pyrazole compounds. The present invention also pertains to the use of such compounds in the treatment of diseases and disorders that are ameliorated by treatment with a neutral antagonist of... Agent: Swanson & Bratschun, L.L.C.

20100022612 - Fused heterocycles: e

20100022613 - Compounds having crth2 antagonist activity:

20100022614 - Pharmaceutical composition for external application and adhesive skin patch: Disclosed are a pharmaceutical composition for external application, an adhesive skin patch and others which are improved in a drug release property, transdermal absorbability and stability of a pharmacologically active ingredient contained therein and can reduce the aggravation of irritation to the skin. Specifically disclosed is an adhesive skin patch... Agent: Dilworth & Barrese, LLP

20100022615 - Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions: Activated cytotoxic compounds are described for attachment to targeting molecules for the treatment of a mammalian disease condition which comprise, an activator, a spacer linker, a linker (e.g., self-immolative), and a cytotoxic drug selected from the group consisting of AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES, AMINO-AND-HYDROXY SUBSTITUTED STYRYLSULFONANILIDES, and SUBSTITUTED PHENOXY- AND... Agent: Law Offices Of Khalilian Sira, LLC

20100022616 - 3-(phenoxyphenylmethyl)pyrrolidine compounds: where a and R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing... Agent: Theravance, Inc.

20100022617 - Compositions and methods to control abnormal cell growth: A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. A representative of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide (CCDTHT) was shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight,... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20100022629 - Dietary methods and compositions for enhancing metabolism and reducing reactive oxygen species: This invention relates to methods comprising administering to a subject a dietary composition for modifying cellular metabolism, metabolic production of reactive oxygen species and the resulting level of reactive oxygen species. The invention is drawn to a method comprising a combination of carnitine, lipoic acid and polyphenol, which has the... Agent: Davis, Agnor, Rapaport & Skalny, LLC

20100022630 - Method of treatment using fatty acid synthesis inhibitors: The present invention relates to natural products that possess fatty acid synthesis inhibitor activity and can be used to treat and prevent diseases such as obesity, cancer, diabetes, fungal infections, Mycobacterium tuberculosis infections, malarial infections and other apicomplexan protozoal diseases.... Agent: Merck And Co., Inc

20100022631 - Treatment of hepatic encephalopathy and liver cirrhosis: The compounds D9-tetrahydrocannabinol (THC), cannabidiol (CBD) and capsaicin are useful for prevention, treatment, or both, of hepatic encephalopathy. The compounds capsaicin, 2-arachidonoylglycerol (2-AG), HU-308 and cannabidiol are useful for prevention, treatment, or both, of liver cirrhosis.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100022632 - Use certain diterpene compounds in the treatment of androgen receptor-associated diseases: The present invention discloses certain diterpenes that can be used to inhibit androgen receptor activity, induce apoptosis and block cell cycle progression of androgen receptor-dependent cells. Androgen receptor has been associated with various diseases such as prostate cancer, androgeneic alopecia, breast cancer, acne etc. Accordingly, the present invention further discloses... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100022633 - Cognitive abilities improving agent: A composition containing bark extract from the genus Pinus is described to improve, or prevent a decline in, human cognitive abilities or improve, or prevent symptoms of, neurological disorders in a human. The composition is advantageous for treatment where the human does not suffer from any kind of neurodegenerative disease... Agent: Duane Morris LLP - San Diego

20100022634 - Laidlomycin compositions and methods: An animal feed additive composition comprises an effective amount of a laidlomycin, a carrier, magnesium sulfate, and silicon dioxide. Other embodiments include methods of making the animal feed additive compositions, and the use of a laidlomycin in the manufacture of an animal feed additive for increasing the efficiency of feed... Agent: G Kenneth Smith

20100022635 - Heat shock protein 90 inhibitor dosing methods: The disclosure provides novel dosing regimens for Hsp90 inhibitors for use in the treatment or prevention of a neurodegenerative disorder, an autoimmune disorder, or cancer. The methods involve administering one or more doses of a therapeutically effective amount of at least one Hsp90 inhibitor to a subject in need thereof... Agent: Merchant & Gould PC

20100022636 - Compositions and methods for enhancing the antioxidant status of animals: Compositions suitable for enhancing the antioxidant status of animals containing methionine, taurine, vitamin C, and vitamin E and methods for preparing and using such compositions to enhance the antioxidant status of animals.... Agent: Colgate-palmolive Company

20100022637 - Identification of anti-cancer compounds and compounds for treating huntington's disease and methods of treatment thereof: Small molecule screening via high-throughput screening (HTS) methods was employed to identify compounds useful for treating or preventing cancer (such as compounds that enable cells to overcome E6-oncoprotein-mediated drug resistance) or neurodegenerative disorders (such as Huntington's disease, HD). Compounds were identified that potentiate the lethality of anti-tumor agents as well... Agent: Bryan Cave LLP

20100022638 - Isosorbide nitrates: The present invention relates to new 3-substituted 6-nitrooxy-hexahydrofuro[3,2-b]furane derivatives possessing a superior pharmacological activity in thrombosis and in coronary ischemia models.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100022639 - Methods of inducing weight loss: This invention provides a method for inducing weight loss in an animal by administering to the animal a compound which reduces the expression and/or secretion of neuropeptide Y (NPY). The effect may be accomplished directly, indirectly, or humorally. Preferably, administration of this compound has the effect of increasing malonyl CoA... Agent: Hunton & Williams LLP Intellectual Property Department

20100022640 - Esters of 2-phenylalkanenitriles and antifungal compositions containing them: Esters of 2-phenylalkanenitriles, such as 3-acetoxy-2-(2-chloro-5-(difluoromethoxy)phenyl)propanenitrile and 3-acetoxy-2-(4-chlorophenyl)propanenitrile, and compositions containing such esters, are useful as fungicides at very low concentrations.... Agent: Leonard P Miller

20100022641 - Solid forms of selective androgen receptor modulators: The present invention relates to solid forms of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.... Agent: Pearl Cohen Zedek Latzer, LLP

20100022642 - Dermatological/cosmetic compositions comprising a retinoid and benzoyl peroxide: Dermatological/cosmetic compositions contain, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and a gelling system comprising at least two categories of compounds.... Agent: Buchanan, Ingersoll & Rooney PC

20100022643 - Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers: The present invention provides compositions comprising at least one GHB moiety bonded to at least one physiologically compatible carrier molecule. The compositions can enhance the uptake of the drug, deliver effective therapeutic doses in a time-delayed fashion, or can target specific organs.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100022644 - Peroxycarboxylic acid compositions with reduced odor: The present invention relates to compositions of peroxycarboxylic acid that have reduced odor compared to conventional peroxycarboxylic acid compositions, methods employing these reduced-odor compositions, and methods of making these compositions. Typically, the reduced-odor compositions include an amine oxide surfactant.... Agent: Ecolab Inc.

20100022645 - Pkc-activating compounds for the treatment of neurodegenerative diseases: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20100022646 - method of neutralising organoboronates with acids: The use of specified compounds for the manufacture of a medicament for therapeutically neutralising an organoboronate drug. The specified compounds are typically hydroxy fatty acids or hydroperoxy fatty acids, for example 9(S)-HODE, 8(S)-HETRE or 8(S)-HEPE, or their salts or prodrugs. The organoboronate drug may be TRI 50c or a salt... Agent: Bozicevic, Field & Francis LLP

20100022647 - High arachidonic acid producing strains of yarrowia lipolytica: Engineered strains of the oleaginous yeast Yarrowia lipolytica capable of producing greater than 10% arachidonic acid (ARA, an ω-6 polyunsaturated fatty acid) in the total oil fraction are described. These strains comprise various chimeric genes expressing heterologous desaturases, elongases and acyltransferases, and optionally comprise various native desaturase and acyltransferase knockouts... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100022648 - Oral use of at least one monounsaturated fatty acid for hair improvement: The present invention relates to the cosmetic use by the oral route of at least one monounsaturated fatty acid, a salt thereof and/or an ester thereof, preferably petroselinic acid, for improving the quality of the hair and/or the appearance of the hair, in particular for preventing and/or treating the changes... Agent: Oliff & Berridge, PLC

20100022649 - Pharmaceutical composition and procedure to treat and prevent prostatic hyperplasia and prostatitis from the royal palm (roystonea regia) fruits: A method for treating and/or preventing BPH prostatitis, alopecia and hirsutism including administering a medication of the pharmaceutical composition obtained from the green or mature fruits of Roystonea regia including a mixture of primary fatty acids with 8 to 28 carbon atoms, the fatty acid selected from the group consisting... Agent: Lackenbach Siegel, LLP

20100022650 - Benzamide derivatives as ep4 receptor agonists: m

20100022651 - Method for increasing hair growth: The present invention provides a method for stimulating hair growth, which comprises applying a composition containing a combination of a creatine compound and carnitine. The composition may further comprise 5′-AMP and NADH. Such a composition is effective in stimulating cell proliferation in the hair bulb of hair plugs.... Agent: The Estee Lauder Cos, Inc

20100022652 - Antimicrobial and anticoagulant compositions and methods: A composition may include a combination of at least one chelating agent and at least one antioxidant agent, the combination may have a fractional inhibitory concentration coefficient of about 0.5 or less and/or an INR of > about 2.82.... Agent: Tyco Healthcare Group Lp

20100022653 - Process for the preparation of and crystalline forms of optical enantiomers of modafinil: The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 8.54, 4.56, and 3.78 Å, and a process for the preparation thereof.... Agent: Ross J. Oehler Cephalon, Inc.

20100022654 - Antimicrobial compositions: Antimicrobial compositions are provided that include a hydroalcoholic solvent system comprising a lower C2-C5 alcohol and water; a cationic antimicrobial agent such as chlorhexidine gluconate; a fatty component containing at least one free hydroxyl group, such as a C12-C21 fatty alcohol, a C12-C21 fatty ester, a C12-C21 fatty ether, a... Agent: 3m Innovative Properties Company

20100022656 - Optically active phenylethanol amines and preparing method thereof: The invention provides compounds of formula (I) having (−) or (+) configuration, or pharmaceutically acceptable salts thereof, wherein R1 is H or halo; R2 is CF3, CN, or halo; R3 is linear or branched alkyl having 1 to 6 carbon atoms, or cycloalkyl having 3 to 6 carbon atoms. The... Agent: Seed Intellectual Property Law Group PLLC

20100022655 - Therapeutic agents for the treatment of lymphoid malignancies: Methods—for treatment and prevention of lymphoid malignancies, including, but not limited to acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute Myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods include administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride) or a derivative, pharmaceutically acceptable... Agent: Calfee Halter & Griswold, LLP

20100022657 - Treatment of faecal incontinence and other conditions with 1r, 2s-methoxamine: 1R,2S-Methoxamine may be used topically for effective treatment of faecal incontinence at low doses without local or systemic side effects, for example, without affecting blood pressure. 1R,2S-Methoxamine may be used to treat other disturbances and disorders of the gastrointestinal, as a pressor agent, as a nasal decongestant and in ophthalmology,... Agent: Leon R. Yankwich

20100022659 - Methods and compositions for the treatment of cns-related conditions: The invention provides methods and compositions for the treatment of dementia-related conditions, such as Parkinson's disease and Alzheimer's disease.... Agent: Adamas Pharmaceuticals, Inc.

20100022658 - Methods for treating cognitive impairment in humans: Cognitive impairments in humans with multiple sclerosis are treated and cognition is improved with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100022660 - Foaming alcohol compositions with selected dimethicone surfactants: Foaming alcohol compositions with selected dimethicone surfactants are disclosed. The dimethicone surfactants are PEG-8 to PEG-12 linear dimethicone surfactants and in particular PEG-10 linear dimethicone surfactant. The compositions are useful as antimicrobial products and in particular handcare or skincare products.... Agent: Ecolab Inc.

20100022661 - Controlled release compositions for modulating free-radical induced damage and methods of use thereof: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with free-radical modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).... Agent: Wilson, Sonsini, Goodrich & Rosati

20100022662 - Modified comb copolymers: The present invention relates to modified comb copolymers comprising special structural units, which are produced by converting SMA resins and optionally special copolymers with an AB block copolymer structure with a mixture of at least one polyalkylene oxide monoamine and at least one amino alcohol, with a mixture of at... Agent: Gerstenzang, William C. Norris Mclaughlin & Marcus, Pa

20100022663 - Methods for manufacturing amino acid mimetic copolymers and use of same: Biocompatible polymers are manufactured to include an ammo acid mimetic monomer and one or more hydrophobic acrylate monomers. The amino acid mimetic monomers are selected to mimic the side chain of the amino acids asparagine or glutamine. The amino acid mimetic monomer can be a methacryloyl or acryloyl derivative of... Agent: Squire, Sanders & Dempsey LLP

20100022665 - Oil-in-water emulsion cosmetic composition and method for producing the same: To provide an oil-in-water emulsion cosmetic composition obtained by using a polyglycerin fatty acid ester as a surfactant, which has high stability against temperature and is excellent in tactile sensation, and a method for producing the same, the present invention provides an oil-in-water emulsion cosmetic composition, wherein the composition comprises... Agent: Knobbe Martens Olson & Bear LLP

20100022664 - Process for the partial hydrogenation of fatty acid esters: Suggested is a process for the manufacture of unsaturated fatty acid alkyl esters or glycerides having a total content of C 18:1 of about 30 to about 80 Mol-% by partial hydrogenation of unsaturated fatty acid esters having a total content of (C18:2+C18:3) of at least 65 Mol-%—calculated on the... Agent: Fox Rothschild LLP